Antibodies to quetiapine haptens and use thereof
Disclosed is an antibody which binds to quetiapine, which can be used to detect quetiapine in a sample such as in a competitive immunoassay method. The antibody can be used in a lateral flow assay device for point-of-care detection of quetiapine, including multiplex detection of aripiprazole, olanzapine, quetiapine, and risperidone in a single lateral flow assay device.
1. An isolated antibody or a binding fragment thereof, which specifically binds to quetiapine but does not bind to aripiprazole, olanzapine and risperidone, and which is generated in response to a conjugate of a compound of Formula I and an immunogenic carrier,
wherein:
R 1 is H,
CH 2 NH 2 , or CH 2 NHC(O)(CH 2 ) m CO 2 H;
R 2 is H,
CH 2 NH 2 , or CH 2 NHC(O)(CH 2 ) m CO 2 H;
R 3 is H; provided that either R 1 or R 2 must be H, and further provided that both R 1 and R 2 may not be H simultaneously;
m is 1, 2, 3, 4, or 5; and
n is 1, 2, 3, 4, or 5, wherein said immunogenic carrier is covalently linked to either R 1 or R 2 , provided when said immunogenic carrier is linked to R 1 , R 2 must be H and R 1 must not be H, and wherein said immunogenic carrier is linked to R 2 , R 1 must be H and R 2 must not be H.
2. The antibody of claim 1 , wherein the immunogenic carrier is a protein selected from the group consisting of keyhole limpet hemocyanin, bovine thyroglobulin, and ovalbumin.
3. The antibody of claim 1 , wherein the antibody binding fragment is selected from the group of fragments consisting of Fv, F(ab′), F(ab′)2, scFv, minibody and diabody fragments.
4. The antibody of claim 1 , wherein the antibody is a monoclonal antibody.
5. An assay kit comprising the antibody or binding fragment thereof of claim 1 .
6. An assay device comprising the antibody or binding fragment thereof of claim 1 .
7. The assay device of claim 6 wherein the device is a lateral flow assay device.
8. A method of detecting quetiapine in a sample, the method comprising:
(i) contacting a sample with the antibody or binding fragment thereof of claim 1 labeled with a detectable marker, wherein the labeled antibody or binding fragment thereof and quetiapine present in the sample form a labeled complex; and
(ii) detecting the labeled complex so as to detect quetiapine in the sample.
9. A competitive immunoassay method for detecting quetiapine in a sample, the method comprising:
(i) contacting a sample with the antibody or binding fragment thereof of claim 1 , and with quetiapine or a competitive binding partner of quetiapine, wherein one of the antibody or binding fragment thereof and the quetiapine or competitive binding partner thereof is labeled with a detectable marker, wherein the antibody or binding fragment thereof, or the quetiapine or competitive binding partner thereof not labeled with the detectable marker is attached to a support, and wherein sample quetiapine competes with the quetiapine or competitive binding partner thereof for binding to the antibody or binding fragment thereof; and
(ii) detecting the label so as to detect sample quetiapine.
10. The method of claim 9 , wherein the quetiapine or competitive binding partner thereof is labeled with the detectable marker.
11. The method of claim 9 , wherein the antibody or binding fragment thereof is labeled with a detectable marker.
12. The method of claim 9 , wherein the immunoassay is performed on a lateral flow assay device and the sample is applied to the device.
13. The method of claim 8 or 9 , further comprising detecting the presence of one or more analytes in addition to quetiapine.
14. The method of claim 13 , wherein the one or more analytes are anti-psychotic drugs other than quetiapine.
15. The method of claim 14 , wherein the anti-psychotic drugs other than quetiapine are selected from the group consisting of: risperidone, paliperidone, aripiprazole, olanzapine, and metabolites thereof.